Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (GA-3)

University Hospital, Gentofte, Copenhagen

Status: Completed

Conditions: Glucose Metabolism Disorders

Treatments: Other: GLP-1 receptor antagonist Exendin[9-39]; Other: GIP-A; Other: Placebo; Other: GIP-A + Exendin[9-39]

Study type: Interventional

Funder types: Other

Identifiers

NCT03133741

UHG-CFD-GIPANTA-3

Details and patient eligibility

About

Delinieation of GIP's effects during an oral glucose tolerance test (OGTT) in humans using GIP receptor antagonisation.

Full description

Aim: To evaluate the role of GIPR signalling in postprandial physiology, including bone and glucose homeostasis, using a naturally occurring GIP fragment (GIP-A), which antagonises the GIPR.

Eighteen healthy men (age 18-70 years, BMI 19-35 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin[9-39], C) GIP-A + Exendin[9-39], or D) saline (placebo).

Enrollment: 18 patients

Sex: Male

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Normal kidney function, liver function and hemoglobin levels.

Exclusion criteria

• Medication, Diabetes type 1 or 2, first degree relatives with Diabetes type 2

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

18 participants in 4 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Saline

Treatment:

Other: Placebo

GIP-A

Other group

Description:

Infusion of GIP-A alone as study tool.

Treatment:

Other: GIP-A

GLP-1 receptor antagonist Exendin[9-39]

Other group

Description:

Infusion of GLP-1 receptor antagonist Exendin\[9-39\] alone as study tool.

Treatment:

Other: GLP-1 receptor antagonist Exendin[9-39]

GIP-A + Exendin[9-39]

Other group

Description:

Infusion of GIP-A + GLP-1 receptor antagonist Exendin\[9-39\] together as study tools.

Treatment:

Other: GIP-A + Exendin[9-39]